SoftBank Group has announced a strategic joint venture with Tempus AI, an AI-driven medical data analysis company. Revealed by SoftBank’s CEO Masayoshi Son, this partnership signifies another major investment in AI by SoftBank, following a $200 million investment in Tempus earlier this year. Tempus, known for its genomic testing and AI-powered treatment recommendations, aims to bring its advanced healthcare services to Japan. The joint venture, set to close in July, involves a $93 million investment from each party. Google has also shown substantial support for Tempus, bolstering its AI capabilities and contributing to its growth. Tempus recently went public on Nasdaq, achieving a market cap of $6 billion and collaborating with top pharmaceutical companies and academic medical centers. This partnership with SoftBank positions Tempus AI as a leader in AI-powered healthcare services, promising significant advancements in medical diagnostics and treatment in Japan.
SoftBank Partners with Tempus AI to Revolutionize Healthcare in Japan
SoftBank and Tempus AI join forces to enhance healthcare in Japan with AI-driven solutions.
1–2 minutes
TOP STORIES
The New York Times accuses Brave of illegally scraping and distributing its content …
The New York Times accuses Brave of illegally scraping and distributing its content …
The event in Brooklyn revealed a strong community backlash against AI and data centers …
The event in Brooklyn revealed a strong community backlash against AI and data centers …
A federal judge has ruled that xAI must face the NAACP lawsuit over permit violations …
A federal judge has ruled that xAI must face the NAACP lawsuit over permit violations …
